Analysis of surgical treatment of Masaoka stage III-IV thymic epithelial tumors

2018 ◽  
Vol 66 (12) ◽  
pp. 731-735 ◽  
Author(s):  
Kazutoshi Hamanaka ◽  
Tsutomu Koyama ◽  
Shunichiro Matsuoka ◽  
Tetsu Takeda ◽  
Kentaro Miura ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Stage Iii ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Masaoka Stage

scholarly journals Video-assisted thoracoscopy versus open approach in patients with Masaoka stage III thymic epithelial tumors

2019 ◽  
Vol 8 (3) ◽  
pp. 962-967
Author(s):  
Liru Chen ◽  
Chen Xie ◽  
Qing Lin ◽  
Quan Xu ◽  
Yangchun Liu ◽  
...  
Keyword(s):  
Stage Iii ◽  
Open Approach ◽  
Thymic Epithelial Tumors ◽  
Video Assisted ◽  
Epithelial Tumors ◽  
Masaoka Stage

A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7104-7104
Author(s):  
Silvia Park ◽  
Keunchil Park ◽  
Myung-ju Ahn ◽  
Jin Seok Ahn ◽  
Jong-Mu Sun ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Phase Ii ◽  
Thymic Carcinoma ◽  
Locally Advanced ◽  
Complete Resection ◽  
Stage Iii ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Masaoka Stage ◽  
Prospective Phase

7104 Background: Thymic epithelial tumors (TETs), thymoma and thymic carcinoma, are the most common tumor of the anterior mediastinum. Initial complete resection is the most powerful prognostic indicator of survival. However, it is obviously related to stage. Here, we report the result of a prospective phase II study of neoadjuvant docetaxel/cisplatin in patients with locally advanced TETs. Methods: In this open-label, phase II, nonrandomized study, patients with histologically proven, Masaoka stage III/IV TETs at presentation were enrolled. Patients received docetaxel 75mg/m2 I.V for 1 hr, followed by I.V cisplatin 75mg/m2 over 1.5hr on day 1 of every 3 week. After 3 cycles of chemotherapy, subsequent surgical resection was performed, if resectable. Results: From March 2007 to July 2011, a total of 27 TETs patients were entered into the trial. The median age was 54 (range, 15-68), and Masaoka stage at presentation was III (n=8, 29.6%), IVA (n=17, 63.0%), and IVB (n=2, 7.4%). Histologic type by the WHO includes type B1 (n=2, 7.4%), B2 (n=3, 11.1%), B3 (n=5, 18.5%), and thymic carcinoma designated as type C (n=16, 59.3%). After completion of neoadjuvant chemotherapy, 17 (63.0%) achieved PR and 10 (37.0%) had SD. Nineteen patients (70.4%) underwent surgical resection, and 8 patients did not (surgeons’ decision, n=5; patients’ refusal, n=2; radiation therapy, n=1). Of the 19 patients undergoing surgical resection, 17 (89.5%) had complete resections and 2 (10.5%) did not. Major side effects of chemotherapy include grade 3 anorexia (n=1), nausea (n=2), diarrhea (n=3), alopecia (n=1). After completion of surgical resection, adjuvant therapy was performed as follows: radiotherapy (RT, n=8), chemotherapy (CTx, n=6), radiotherapy with chemotherapy (RT + CTx, n=2) and observation (n=3). Overall, 4yr OS and PFS was 79.4% and 40.6%. Patients with complete resection showed 93.8% of 4yr OS and 50.2% of 4yr PFS whereas patients without complete resection showed 47.6% of 4yr OS and 26.7% of 4yr PFS, respectively (OS, p=0.06; PFS, p=0.27). Conclusions: Neoadjuvant docetaxel/cisplatin was well tolerated and feasible, and improved the surgical respectability in patients with advanced TETs.

scholarly journals Prognostic Significance of Metabolic Parameters by 18F-FDG PET/CT in Thymic Epithelial Tumors

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 712
Author(s):  
Joohee Lee ◽  
Young Seok Cho ◽  
Jhingook Kim ◽  
Young Mog Shim ◽  
Kyung-Han Lee ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Fdg Pet ◽  
Univariate Analysis ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Masaoka Stage ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Background: Imaging tumor FDG avidity could complement prognostic implication in thymic epithelial tumors. We thus investigated the prognostic value of volume-based 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT parameters in thymic epithelial tumors with other clinical prognostic factors. Methods: This is a retrospective study that included 83 patients who were diagnosed with thymic epithelial tumors and underwent pretreatment 18F-FDG PET/CT. PET parameters, including maximum and average standardized uptake values (SUVmax, SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured with a threshold of SUV 2.5. Univariate and multivariate analysis of PET parameters and clinicopathologic variables for time-to-progression was performed by using a Cox proportional hazard regression model. Results: There were 21 low-risk thymomas (25.3%), 27 high-risk thymomas (32.5%), and 35 thymic carcinomas (42.2%). Recurrence or disease progression occurred in 24 patients (28.9%). On univariate analysis, Masaoka stage (p < 0.001); histologic types (p = 0.009); treatment modality (p = 0.001); and SUVmax, SUVavg, MTV, and TLG (all p < 0.001) were significant prognostic factors. SUVavg (p < 0.001) and Masaoka stage (p = 0.001) were independent prognostic factors on multivariate analysis. Conclusion: SUVavg and Masaoka stage are independent prognostic factors in thymic epithelial tumors.

Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): An observational report.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17546-e17546
Author(s):  
Giovenzio Genestreti ◽  
Marco Angelo Burgio ◽  
Luca Ampollini ◽  
Luigi Rolli ◽  
Stefano Sanna ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Clinical Staging ◽  
Thymic Epithelial Tumors ◽  
Adjuvant Therapies ◽  
Epithelial Tumors ◽  
Stage Ivb ◽  
Type 3

e17546 Background: Thymic epithelial tumors (TETs) consist of a series of neoplasm arising from the anterior mediastinum. Due to its rarity, large-scale prospective trials have been lacking. This retrospective multicenter analysis aimed to evaluate clinical outcome and clinico-pathological features of TETs after surgery resection and adjuvant treatments as chemotherapy and/or radiotherapy. Methods: All medical records about TETs surgically resected between 2000 and 2007 and eventually treated with adjuvant therapies (chemotherapy and/or radiotherapy) were reported. Surgical procedures included complete removal of thymic, mediastinal fat tissue and any suspicious lesions. Histological classification has been made in according to WHO criteria and Masaoka staging system was adopted. Adjuvant chemotherapy was represented by anthracycline and platin-based regimen whereas adjuvant radiotherapy was delivered on irradiation field covered primary tumor bed. Overall survival was calculated from the date of diagnosis until patient death or last follow-up visit. Disease free-survival was defined the interval from operation until date of recurrence. Results: Overall 32 patients were analyzed of whom 12 (37%) male and 20 (63%) female. Median age was 61 years (range: 33 - 86). At the beginning of their oncologic history 14 (42%) patients had miastenia. Overall at clinical staging there were 19 (60%) stage I, 4 (12%) stage II, 4 (12%) stage III, and 5 (16%) stage IVb at radiological staging. The histological exam reported: 5 (16%) A tumor type, 11 (34%) AB type, 3 (10%) B1 type, 3 (10%) B2 type, 8 (24%) B3 type, 2 (6%) C type. At pathological staging there were: 18 (56%) stage I, 7 (22%) stage II, 2 (6%) stage III and 5 (16%) stage IVb. Post-surgical therapies were represented by chemotherapy in 2 (6%) patients and radiotherapy in 13 (41%) patients. Disease relapse was recorded in 1 (3%) patient after 27 months from diagnosis. Overall survival rate at 78 months is 86% (CI: 66-100). Conclusions: TETs are rare and indolent cancer. Surgery offers the good perspectives eventually improved with adjuvant therapies like chemotherapy and/or radiotherapy. Supported by GIPO.

Fluorodeoxyglucose Positron Emission Tomography Can Provide Useful Information for Differentiating Thymic Epithelial Tumors

2017 ◽  
Vol 66 (04) ◽  
pp. 345-349 ◽  
Author(s):  
Takanori Ayabe ◽  
Kazuyo Tsuchiya ◽  
Kunihide Nakamura ◽  
Masaki Tomita
Keyword(s):  
Positron Emission Tomography ◽  
High Risk ◽  
Low Risk ◽  
Emission Tomography ◽  
Histologic Type ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Masaoka Stage ◽  
Positron Emission ◽  
Stage Disease

Background We examined the usefulness of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting the World Health Organization (WHO) histologic type and Masaoka stage of thymic epithelial tumors. Methods A total of 73 patients with thymic epithelial tumors who underwent preoperative FDG-PET were included. Relationships between the maximum standardized uptake value (SUVmax) and WHO histologic type and the Masaoka stage of the tumor were examined. Differences in SUVmax between the various groups were calculated. To avoid the effect of the tumor size on SUVmax, the ratio of SUVmax to tumor size (SUVmax/T) was also examined. Results There was a significant relationship between SUVmax and WHO histologic type. SUVmax of high-risk thymomas (types B2 and B3) was significantly higher than that of low-risk thymomas (types A, AB, and B1). SUVmax of thymic carcinomas was also significantly higher than those of the low-risk and high-risk groups. The relationship between the SUVmax/T and WHO histologic type showed more significant results. SUVmax and SUVmax/T showed higher values in patients with advanced Masaoka stage disease than in those with early-stage disease. Conclusions FDG-PET can provide useful information for differentiating thymic epithelial tumors. The SUVmax/T is more useful than the SUVmax for differentiating between low-risk and high-risk thymomas.

Sign in / Sign up

Export Citation Format

Share Document